Background {#sec0005}
==========

In the United States, diagnostic testing capacity for SARS-CoV-2, the virus causing coronavirus disease 2019 (COVID-19), has increased ([@bib0005]). A key public health intervention to mitigate the spread of COVID-19 is timely testing for early diagnosis of infections ([@bib0060]). Early in the epidemic, SARS-CoV-2 PCR testing was prioritized in clinical settings for symptomatic people who were: hospitalized, healthcare workers, or at high risk for complications (Centers for Disease Control and Prevention). Many diagnostic tests for SARS-CoV-2 have been developed and received Emergency Use Authorizations (EUA) by the U.S. Food and Drug Administration (FDA). Yet, concerns exist about the clinical sensitivity and specificity of those tests, particularly with regard to the frequency of false negative test results, which might lead missed infections and ongoing transmission ([@bib0090]).

Although repeat testing has been suggested as a way to increase diagnostic yield, there are sparse data on the yield of repeat testing ([@bib0045], [@bib0055]). Moreover, repeat testing further limits supply and, among hospitalized patients, necessitates continued isolation and use of personal protective equipment, a limited commodity in the US ([@bib0050]). Therefore, it is of high importance for clinicians to understand the diagnostic yield of repeat testing for SARS-CoV-2. We aimed to provide insight into the diagnostic yield of repeat testing for SARS-CoV-2 within a large health system in Los Angeles, and highlight the clinical scenarios of discordant results in inidividuals with an initial negative test.

Methods {#sec0010}
=======

We reviewed all SARS-CoV-2 tests within the UCLA Health System collected between March 9th and April 29th, 2020. Nasopharyngeal specimens were the preferred specimen collection method at our institution. During the time period of the study, nasal and oropharyngeal swabs were not used. For inpatients with concern for lower respiratory tract disease, clinicians could order lower respiratory tract specimens (e.g. -- expectorated sputum, bronchoalveolar lavage (BAL), tracheal aspirate).

Testing was either performed at the UCLA clinical microbiology laboratory or was sent to a commercial laboratory ([@bib0070]). Testing at UCLA was done using three tests: 1) the U.S. Centers for Disease Control and Prevention's (CDC's) 2019-nCoV Real-Time Reverse Transcriptase (RT-) PCR Diagnostic Panel protocol (Atlanta, GA), which uses probes targeting the nucleocapsid gene (N1 & N2) of SARS-CoV-2 (Centers for Disease Control and Prevention); 2) the Diasorin Simplexa COVID-19 Direct RT-PCR (Diasorin Molecular LLC, Cypress, CA), which has two different targets, the S gene encoding for the spike glycoprotein of SARS-CoV-2 and the ORF1ab region encoding well-conserved non-structural proteins ([@bib0035]); or 3) the TaqPath COVID-19 Combo Kit (Thermo Fisher Scientific Inc., Waltham, MA), which uses probes targeting ORF1ab, N, and S genes ([@bib0080]). Quest Diagnostics utilized the Quest SARS-CoV-2 rRT-PCR test (Quest Diagnostics, San Juan Capistrano, CA), which targets two regions of the N gene (N1 & N3) ([@bib0070]). All assays received EUA by the FDA for the qualitative detection of SARS-CoV-2 RNA in upper and lower respiratory specimens. Each specimen submitted for testing was tested using only one of the aforementioned diagnostic assays.

We defined multiple tests performed within the same patient as repeat tests. We excluded cases where the initial test was inconclusive. We report total number of tests, overall test positivity, and the number of patients with repeat tests and discordant results.

Results {#sec0015}
=======

In total, there were 10,165 SARS-CoV-2 tests performed and 6.2% (630/10,165) were positive. There were 906 patients with repeat test results, 2 were excluded due to inconclusive initial results. Among the 904 total cases, 808 (89.4%) were initially negative and 96 (10.6%) were initially positive. Those 904 patients accounted for 2,108 tests with an overall positivity of 9.9% (n = 209). The vast majority (93.7%) of those tests were performed on nasopharyngeal specimens and 65% were performed on the Diasorin platform. The number of tests and SARS-CoV-2 positivity by diagnostic assay and specimen type are shown in [Table 1](#tbl0005){ref-type="table"} .Table 1SARS-CoV-2 tests performed among 904 patients with repeat tests from March 9th to April 29th, 2020 at UCLA Health System in Los Angeles, CA, USA. Total tests and SARS-CoV-2 positivity are reported by diagnostic assay and specimen type.Table 1SARS-Cov-2 Test Positivity\
n (%)Total TestsAll Tests209 (9.9)2108Diagnostic AssayDiasorin Simplexa COVID-19 Direct RT-PCR118 (8.6)1370CDC 2019-nCoV RT-PCR Diagnostic Panel56 (15.6)358TaqPath COVID-19 Combo Kit35 (9.2)380Specimen TypeNasopharyngeal195 (9.9)1977Bronchoalveolar lavage9 (9.3)97Sputum2 (10.5)19Tracheal specimen3 (30.0)10Other0 (0)5

Among the 96 patients with initial positive tests, 56 (58.3%) were repeated once, 24 (25.0%) were repeated twice, eight (8.3%) were repeated thrice, and eight (8.3%) were repeated four or more times. Repeat testing among positive cases was often done for infection control practices and for discharge planning. Among those with an initial positive test, 50% had a subsequent negative result (48/96); the median time between positive and negative tests was 16 days (interquartile range: 9 -- 27 days). ([Figure 1](#fig0005){ref-type="fig"} , Panel A)Figure 1Panel (A) Repeat SARS-CoV-2 testing results among patients with an initial positive test result for SARS-CoV-2. Panel (B). Repeat SARS-CoV-2 testing results among patients with an initial negative test result for SARS-CoV-2.Figure 1

Among the 808 patients with an initial negative test, 646 (80.0%) were repeated once, 110 (13.6%) repeated twice, 39 (4.8%) were repeated thrice, and 13 (1.6%) were repeated four times; fifteen (1.9%) subsequently tested positive. ([Figure 1](#fig0005){ref-type="fig"}, Panel B) Clinical information was not available for one case. In three instances, patients were transferred from an outside facility where they had a positive SARS-COV-2 test. All transferred patients had an negative test on arrival, but a subsequent positive test within 24 hours.

There were 11 cases with an initial negative SARS-CoV-2 test, without a known prior positive SARS-CoV-2 test, and with reasons for repeat testing available for review. All of the initial tests were done on nasopharyngeal specimens and ten of the cases tested positive the second time. Six individuals with an initial negative test and a subsequent positive test were employed as healthcare workers (HCWs). The clinical scenarios for testing, as well as the specimen type, setting, diagnostic assay, and possible reasons for the initial negative result are presented in [Table 2](#tbl0010){ref-type="table"} . Testing prior to infection was likely in one case, as there were 20 days between the negative test and the development of symptoms. In three cases, pre-symptomatic testing was the likely explanation, as symptoms of acute illness developed after the initial test. In the remaining cases, possible reasons for the initial negative test result were inadequate specimen collection or inconsistent viral shedding.Table 2Review of clinical and testing data for patients within a large health system in Los Angeles, CA who underwent repeat testing for SARS-CoV-2, had an initial negative test and a subsequent positive test, and were without a known prior positive SARS-CoV-2 test result.Table 2Initial Negative TestSubsequent Positive TestClinical ScenarioSetting/ Specimen TypeAssay[\*](#tblfn0005){ref-type="table-fn"}Scenario for repeat testingDays after initial testSetting / Specimen TypeAssay[\*](#tblfn0005){ref-type="table-fn"}Possible reason for negative testPresented to the hospital with 10-14 days of fever, fatigue, dyspnea, cough and imaging showing bilateral infiltratesEmergency Department / NPAWorsening hypoxemia and high clinical suspicion for infection2Inpatient / NP + SputumA + BPoor sampling or Inconsistent viral sheddingPatient with history of liver transplantation and end-stage renal disease who presented with 1 day of fever, myalgias, cough, and diarrheaOutpatient / NPAWorsening fever and dyspnea2Inpatient / NPAPoor sampling or Inconsistent viral sheddingHCW with history of asthma, presented with 2 days of chest tightness and dyspnea, both relieved by inhalers; reported having a roommate with COVID-19Emergency Department / NPBNew symptoms - 3 days of fever and progressive cough with dyspnea7Emergency Department / NPAPre-symptomaticHCW who presented with 6 days of dry cough, post-nasal drip, and headache.Outpatient / NPADeveloped one day of fevers and chills21Outpatient / NPAPrior to infectionHCW reporting 1-day of rhinorrhea, cough, and chest tightnessOutpatient/NPADeveloped symptoms of fatigue, arthralgias, fever, cough, and nausea for 4 days6Outpatient / NPAPre-symptomaticHCW, reporting 4-days of sinus congestion and sore throatOutpatient/NPBDeveloped 1 day of fever, chills, diarrhea, and cough; domestic partner diagnosed with COVID19 after initial testing4Outpatient / NPAPre-symptomaticHCW reporting 2 days of sore throat and work exposure 3 days priorOutpatient/NPADeveloped 2 days of fever, myalgias, and arthralgias3Outpatient / NPAPoor sampling or Inconsistent viral sheddingHCW reporting 1-day of fever, chills, myalgiasOutpatient/NPCOngoing fevers, cough, and fatigue8Outpatient / NPCPoor sampling or Inconsistent viral sheddingPatient was admitted to the hospital with fever and found to have septic arthritis of the knee. Initial testing done on admissionInpatient/NPATesting performed prior to surgery for epidural abscess4Inpatient / NPAPoor sampling or Inconsistent viral sheddingPatient admitted to the hospital after being found unconscious at home. Cardiac arrest in Emergency Room. Chest imaging showed bilateral infiltrates.Inpatient/NPARepeat testing done per infection control policy0Inpatient / SputumBPoor sampling or Inconsistent viral sheddingPatient residing in a skilled nursing facility who presented with 1-day history of feverInpatient / NPAPersistent fevers; repeat tests done on hospital days 1, 5, and 99[\*\*](#tblfn0010){ref-type="table-fn"}Inpatient / NPAPoor sampling or Inconsistent viral shedding[^1][^2][^3]

Discussion {#sec0020}
==========

We found that repeat testing for SARS-CoV-2 had low diagnostic yield. Discordant results occurred in only 1.3% of patients with an initial negative test and without a prior diagnosis of SARS-CoV-2 infection. Consideration of the pretest probability alongside the estimated test performance can be used to guide repeat testing ([@bib0090]). For example, our report highlighted that repeat testing might prove useful in HCWs with ongoing exposures, as over half of those with initial negative tests and a subsequent positive test were employed as HCWs.

Other scenarios where repeat testing after a negative test might be useful include when symptoms of COVID-19 develop after a negative test, if inadequate specimen collection is suspected, and in hospitalized patients with high clinical suspicion for COVID-19 ([@bib0045]). Moreover, public health interventions to mitigate the spread of COVID-19 rely on timely testing and early diagnosis of infections, in order to inform isolation, contact tracing, and quarantine efforts, and repeat testing will be needed in these situations ([@bib0060]).

SARS-CoV-2 viral shedding can be variable and the timing related to exposure and symptom onset is important to test result interpretation ([@bib0085], [@bib0105]). Available data suggest SARS-CoV-2 is typically detectable by RT-PCR in the nasopharynx by symptom onset and that viral loads are highest in the nasopharynx in the first week of the infectious course ([@bib0075], [@bib0085], [@bib0105]). In our report, testing prior to infection was the likely explanation in one case and testing prior to symptom onset appeared to be the reason for three cases. In most cases, it was not possible to differentiate between variability in viral shedding and poor specimen collection. While the timing and quality of specimen collection are key, a false negative test result is still possible. Data regarding the clinical sensitivity remain quite limited. Preliminary reports suggest that nasopharyngeal specimens might have up to 27% false negativity and a systematic review estimated false negatives in 2% to 29% of specimens, although the quality of evidence was low ([@bib0010], [@bib0095]).

Retesting positive cases was recommended as a way to document viral clearance and remove isolation precautions (Centers for Disease Control and Prevention). In our report, approximately half of those with an initial positive test had a subsequent negative test. Prior reports have documented prolonged duration of SARS-CoV-2 positivity by RT-PCR, up to 6 weeks in some cases ([@bib0040], [@bib0065], [@bib0100]). RT-PCR tests are characteristically sensitive, but are unable to discriminate between the presence of replicating virus and non-infectious remnants that contain nucleic acid targets. However, emerging evidence now suggests there is very low likelihood of infectivity, as measured by culturing viable SARS-CoV-2, if more than 8 days has elapsed since time of symptom onset ([@bib0015], [@bib0085]).

Our results should be considered in light of the following limitations. First, our study was performed within one health system and might not be generalizable to other settings. The report highlighted instances where repeat testing yielded discordant results in a clinical setting and might not be generalizable to repeat testing as part of a broader public health response. Second, we could not assess differences in tests by anatomic site, as we did not have paired specimens. Nevertheless, we provided data on repeat testing for SARS-CoV-2 within a large health system and highlighted cases where repeat testing improved diagnostic yield. In a clinical setting, repeat testing can be considered based on changes to clinical status and the pre-test probability of infection.
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[^1]: HCW -- healthcare worker; NP -- nasopharyngeal.

[^2]: Assay A -- Diasorin Simplexa COVID-19 Direct RT-PCR (Diasorin Molecular LLC, Cypress, CA), Assay B -- CDC 2019-nCoV Real-Time Reverse Transcriptase (RT-) PCR Diagnostic Panel (CDC, Atlanta, GA), Assay C - TaqPath COVID-19 Combo Kit (Thermo Fisher Scientific Inc., Waltham, MA).

[^3]: Positive result occurred on the fourth test, the second and third test results were negative.
